Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levetiracetam as first-line treatment for neonatal seizures in perinatal asphyxia
2014-000791-26Phase 2Completed
- Sponsor
- CHRU Tours
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of levetiracetam in neonatal seizure and hypoxic-ischemic encephalopathy (HIE), sponsored by CHRU Tours. Primary endpoints: Efficacy of levetiracetam loading dose, Short-term tolerability and 3 more. Started Jan 2017; status: completed.
02
Drugs
levetiracetam
03
Conditions
neonatal seizurehypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on 2014-000791-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000791-26.